Overview

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Status:
Active, not recruiting
Trial end date:
2027-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Citric Acid
Niacinamide
Sildenafil Citrate
Sorafenib
Valproic Acid